These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 9422105)

  • 1. Hepatitis B vaccination of blood donors--a cost-benefit analysis.
    Gesemann M; Gentner P; Scheiermann N
    Beitr Infusionsther Transfusionsmed; 1994; 32():110-2. PubMed ID: 9422105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cost-benefit analysis of blood donor vaccination as an alternative to additional DNA testing for reducing transfusion transmission of hepatitis B virus.
    Fischinger JM; Stephan B; Wasserscheid K; Eichler H; Gärtner BC
    Vaccine; 2010 Nov; 28(49):7797-802. PubMed ID: 20875488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B virus vaccination of blood donors--what costs may be expected?
    Ringwald J; Mertz I; Zimmermann R; Weisbach V; Strasser E; Achenbach S; Seyboth S; Richter E; Eckstein R
    Transfus Med; 2005 Apr; 15(2):83-92. PubMed ID: 15859973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation.
    Tilson L; Thornton L; O'Flanagan D; Johnson H; Barry M
    Eur J Public Health; 2008 Jun; 18(3):275-82. PubMed ID: 18160389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of additional hepatitis B virus nucleic acid testing of individual donations or minipools of six donations in the Netherlands.
    Borkent-Raven BA; Janssen MP; van der Poel CL; de Wit GA; Bonsel GJ; van Hout BA
    Transfusion; 2009 Feb; 49(2):311-9. PubMed ID: 19389213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
    Hung HF; Chen TH
    Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-transfusion hepatitis: the role of hepatitis B antibody.
    Koretz RL; Overby LR; Gitnick GL
    Gastroenterology; 1976 Apr; 70(4):556-61. PubMed ID: 56285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economics of blood screening: in search of an optimal blood screening strategy.
    Chinkhumba J
    Trop Doct; 2006 Jan; 36(1):32-4. PubMed ID: 16483429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique.
    Griffiths UK; Hutton G; Das Dores Pascoal E
    Health Policy Plan; 2005 Jan; 20(1):50-9. PubMed ID: 15689430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Residual risk of transfusion-transmitted human immunodeficiency virus, hepatitis C virus, and hepatitis B virus infections in Italy.
    Gonzalez M; Règine V; Piccinini V; Vulcano F; Giampaolo A; Hassan HJ
    Transfusion; 2005 Oct; 45(10):1670-5. PubMed ID: 16181219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Papua New Guinea Red Cross Blood Transfusion Service: present status and future considerations.
    Tozer RA
    P N G Med J; 1996 Mar; 39(1):38-42. PubMed ID: 9522849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An economic evaluation of universal infant vaccination strategies against hepatitis B in Thailand: an analytic decision approach to cost-effectiveness.
    Vimolket T; Poovorawan Y
    Southeast Asian J Trop Med Public Health; 2005 May; 36(3):693-9. PubMed ID: 16124440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites.
    Kim SY; Billah K; Lieu TA; Weinstein MC
    Am J Prev Med; 2006 Jun; 30(6):498-506. PubMed ID: 16704944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficiency of the incorporation of the hepatitis A vaccine as a combined A+B vaccine to the hepatitis B vaccination programme of preadolescents in schools.
    Navas E; Salleras L; Gisbert R; Dominguez A; Bruguera M; Rodríguez G; Galí N; Prat A
    Vaccine; 2005 Mar; 23(17-18):2185-9. PubMed ID: 15755592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of using hepatitis A/B combined vaccine versus hepatitis B vaccine alone for high-risk heterosexuals.
    Rein DB; Weinbaum CM
    Vaccine; 2008 Oct; 26(42):5331-3. PubMed ID: 18706957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis on economic efficacy regarding previous strategies and current recommendations for vaccination against hepatitis B virus in China].
    Zhang SX; Dang RB; Zhang WD; Liang XF; Cui FQ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Oct; 29(10):1003-8. PubMed ID: 19173882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Costs of running a universal adolescent hepatitis B vaccination programme.
    Wallace LA; Young D; Brown A; Cameron JC; Ahmed S; Duff R; Carman WF; Kitchin NR; Nguyen-Van-Tam JS; Goldberg DJ
    Vaccine; 2005 Dec; 23(48-49):5624-31. PubMed ID: 16099079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of hepatitis A/B versus hepatitis B vaccination for US prison inmates.
    Jacobs RJ; Rosenthal P; Meyerhoff AS
    Vaccine; 2004 Mar; 22(9-10):1241-8. PubMed ID: 15003653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness and cost benefit of viral hepatitis B vaccination in the Slovak Republic.
    Hudecková H; Straka S; Szilágyiová M; Avdicová M; Rusnáková S
    Cent Eur J Public Health; 2002 Dec; 10(4):146-8. PubMed ID: 12528387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost-benefit analysis on immunization of newborns with hepatitis B vaccine in Jinan City].
    Liu ZG; Zhao SL; Zhang YX
    Zhonghua Liu Xing Bing Xue Za Zhi; 1995 Apr; 16(2):81-4. PubMed ID: 7781052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.